No Data
As soon as the news of Japan easing tourist visas for people from China was released, local retail travel stocks surged immediately.
① The Japanese Foreign Minister, Toshimitsu Motegi, announced the relaxation of visa requirements for Chinese tourists to Japan, expected to be implemented in spring 2025. ② After the announcement, retail and tourism-related stocks in Japan rose, with J. Front Retailing Co. soaring by 8.38%, while Isetan Mitsukoshi Holdings and Takashimaya increased by 6.98% and 3.69%, respectively.
J.P. Morgan Keeps Their Buy Rating on ABC-MART (AMKYF)
PolAOL HD, DaiKin ETC (additional) Rating
Upgraded - Bullish Code Stock Name Securities Company Previous Change After---------------------------------------------------<6135> Makino F SMBC Nikko "2" "1" <8750> Dai-ichi Life Holdings Mizuho "Hold" "Buy" <8795> T&D Holdings Mizuho "Hold" "Buy" Downgraded - Bearish Code Stock Name Securities Company Previous Change After-----------------------------------------
Resona HD, Ryohin Keikaku etc (additional) Rating
Upgrades - bullish Code Stock Name Securities Company Previous After ---------------------------------------------------------------- <4062> Ibiden Iwai Cosmo "B" "B+" Downgrades - bearish Code Stock Name Securities Company Previous After ---------------------------------------------------------------- <7839>
Stocks that moved the previous day part1 ABC Mart, Levin T, Aiz etc.
Stock Name <Code> Closing Price on the 4th ⇒ Change from Previous Day * ABC Mart ＜2670＞ 3194 +541 Same-store sales in November increased by 14.7%, expanding from a 6.3% increase in October. * Fujidenki ＜6654＞ 1101 -50 Operating profit for the cumulative third quarter decreased by 1.9%, shifting from a 9.8% increase in the first half. * Mitsukoshi Isetan ＜3099＞ 2366 +142.5 Reports indicate that the requirements for visa issuance for Chinese tourists will be relaxed, leading to a market focus on inbound-related stocks in the afternoon. * IGS ＜4265＞ 332
December 4th [Today's Investment Strategy]
[FISCO Selected Stocks] [Material Stocks] JCR Pharma <4552> 727 yen (12/3) Human growth hormone preparations are the main products. Regarding the blood-brain barrier crossing type α-N-acetylglucosaminidase preparation (JR-446) developed by the company, the first administration to the first subject targeted at mucopolysaccharidosis type 3B (MPS3B) in clinical phase 1/2 trials in Japan was announced. MPS3B is being jointly developed and commercialized with Medipal Holdings <7459>.
No Data